Moleculin Biotech (MBRX) PT Lowered to $14 at Maxim Group, Following Clinical Update
Tweet Send to a Friend
Maxim Group analyst Jason McCarthy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
